Evaluation of Cobimetinib + Vemurafenib Combination Treatment in Patients With Brain Metastasis BRAFV600 Mutated Cutaneous Melanoma
Phase of Trial: Phase II
Latest Information Update: 23 Jan 2018
At a glance
- Drugs Cobimetinib (Primary) ; Vemurafenib (Primary)
- Indications Brain metastases; Malignant melanoma
- Focus Therapeutic Use
- Acronyms CONVERCE
- 18 Jan 2018 Planned End Date changed from 1 Jun 2018 to 1 Jun 2020.
- 18 Jan 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Feb 2019.
- 10 Jun 2017 Biomarkers information updated